A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with gram-negative bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7025-7031

  Vega, Hugo Guillermo Ternavasio De ^a   Mateos Díaz, Ana Marí ^a   Martinez, Jose Antonio ^b   Almela, Manel ^b   Cobos Trigueros, Nazaret ^b   Morata, Laura ^b   De la Calle, Cristina ^b   Sala, Marta ^b   Mensa, Josep ^b   Marcos, Miguel ^a   Sorianob, Alex ^b  

^a INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; PREDNISONE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; GLYCOPEPTIDE; OXAZOLIDINONE DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLADDER CATHETERIZATION; BONE MARROW TRANSPLANTATION; CANDIDA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE SEPSIS; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PROPENSITY SCORE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; BACTEREMIA; DRUG EFFECTS; EMPIRICAL RESEARCH; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; PATHOLOGY; STATISTICAL MODEL; SURVIVAL;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; EMPIRICAL RESEARCH; FEMALE; GLYCOPEPTIDES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LINEZOLID; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; OXAZOLIDINONES; PROPENSITY SCORE; SURVIVAL ANALYSIS;

EID: 84912096004     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03796-14     Document Type: Article

References (37)

1. Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, Lamagni T, Chronias A, Sheridan E. 2011. Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin. Microbiol. Infect. 17: 451-458. http://dx.doi.org/10.1111/j.1469-0691.2010.03262.x.
2. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R, BSAC Working Parties on Resistance Surveillance. 2008. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gramnegative bacteria from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 62(Suppl 2):ii55-ii63. http://dx.doi.org/10.1093 /jac/dkn352.
3. Marcos M, Soriano A, Inurrieta A, Martinez JA, Romero A, Cobos N, Hernandez C, Almela M, Marco F, Mensa J. 2011. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J. Antimicrob. Chemother. 66:2119-2125. http://dx.doi.org/10.1093/jac/dkr231.
4. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, Mensa J. 2009. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J. Antimicrob. Chemother. 63:568-574. http://dx .doi.org/10.1093/jac/dkn514.
5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34: 1589 -1596. http://dx.doi.org/10.1097/01 .CCM.0000217961.75225.E9.
6. Martínez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, Pitart C, Sterzik H, Lopez J, Mensa J. 2010. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob. Agents Chemother. 54: 3590-3596. http://dx.doi .org/10.1128/AAC.00115-10.
7. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. 2010. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob. Agents Chemother. 54:4851-4863. http://dx.doi.org/10.1128/AAC.00627-10.
8. Morata L, Cobos-Trigueros N, Martinez JA, Soriano A, Almela M, Marco F, Sterzik H, Nunez R, Hernandez C, Mensa J. 2012. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 56:4833-4837. http://dx.doi.org/10.1128/AAC.00750-12.
9. Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. 2010. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrugresistant bacteria at intensive-care unit admission. Clin. Microbiol. Infect. 16:902-908. http://dx.doi.org/10.1111/j.1469-0691.2009.03027.x.
10. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno- Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E. 2000. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin. Infect. Dis. 30:368-373. http://dx.doi .org/10.1086/313650.
11. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, Shenone E, Pascale GD, Molinari MP, Cauda R, Viscoli C, Tumbarello M. 2012. Risk factors and mortality of healthcare-associated and commu-nity- acquired Staphylococcus aureus bacteraemia. Clin. Microbiol. Infect. 18:862-869. http://dx.doi.org/10.1111/j.1469-0691.2011.03679.x.
12. Søgaard M, Norgaard M, Dethlefsen C, Schonheyder HC. 2011. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a populationbased cohort study. Clin. Infect. Dis. 52:61-69. http://dx.doi.org/10.1093 /cid/ciq069.
13. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. 2006. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947-955. http: //dx.doi.org/10.1378/chest.130.4.947.
14. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54: 755-771. http://dx.doi.org/10.1093/cid/cir935.
15. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in meth-icillin- resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54:621-629. http://dx.doi.org/10 .1093/cid/cir895.
16. Shorr AF, Kunkel MJ, Kollef M. 2005. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56:923-929. http://dx.doi.org/10.1093 /jac/dki355.
17. Falagas ME, Siempos II, Vardakas KZ. 2008. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect. Dis. 8:53-66. http://dx.doi.org/10.1016/S1473-3099(07)70312-2.
18. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C. 2009. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin. Infect. Dis. 48:203-212. http://dx.doi.org/10.1086/595686.
19. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1-45. http://dx.doi.org/10.1086/599376.
20. Wilcox MH, Kunkel MJ, Knirsch C. 2009. Reply to Drekonja and to Lustberg et al. Clin. Infect. Dis. 49:314-315. http://dx.doi.org/10.1086 /600057.
21. Drekonja DM. 2009. Noninferiority of linezolid for skin and bloodstream infections. Clin. Infect. Dis. 49:312, author reply 314-315. http://dx.doi .org/10.1086/600055.
22. Lustberg ME, Schlesinger LS, Mangino JE. 2009. Concerns about "Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study." Clin. Infect. Dis. 49:313, author reply 314-315. http://dx.doi.org/10.1086 /600056.
23. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31:1250-1256. http://dx.doi.org/10 .1097/01.CCM.0000050454.01978.3B.
24. McCabe WR, Jackson GG. 1962. Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch. Intern. Med. 110:856-864.
25. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. http://dx.doi.org/10.1086/524667.
26. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16: 128-140. http://dx.doi.org/10.1016/0196-6553(88)90053-3.
27. Rosenbaum PR, Rubin D. 1984. Reducing bias in observational studies using subclassification on the propensity score. J. Am. Stat. Assoc. 79:516-524. http://dx.doi.org/10.1080/01621459.1984.10478078.
28. Rosenbaum PR, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55. http://dx .doi.org/10.1093/biomet/70.1.41.
29. Thoemmes FJ, Kim ES. 2011. A systematic review of propensity score methods in the social sciences. Multivariate Behav. Res. 46:90-118. http: //dx.doi.org/10.1080/00273171.2011.540475.
30. Austin PC. 2011. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10:150-161. http://dx.doi.org/10.1002 /pst.433.
31. Austin PC. 2007. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J. Thorac. Cardiovasc. Surg. 134:1128-1135. http://dx.doi .org/10.1016/j.jtcvs.2007.07.021.
32. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. 2001. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J. Clin. Epidemiol. 54:387-398. http://dx.doi.org/10.1016/S0895-4356(00)00321-8.
33. Villanueva-Benito I, Solla-Ruiz I, Paredes-Galan E, Diaz-Castro O, Calvo-Iglesias FE, Baz-Alonso JA, Iniguez-Romo A. 2011. Prognostic impact of interventional approach in non-ST segment elevation acute coronary syndrome in very elderly patients. Rev. Esp. Cardiol. 64:853- 861. (In Spanish.) http://dx.doi.org/10.1016/j.recesp.2011.04.022.
34. Sirvent JM, Pineiro L, de la Torre M, Motje M, de Batlle J, Bonet A. 2010. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections. Rev. Esp. Quimioter. 23:27-35.
35. LaPlante KL, Sakoulas G. 2009. Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 53:4549-4555. http://dx.doi.org/10 .1128/AAC.00180-09.
36. Orrick JJ, Johns T, Janelle J, Ramphal R. 2002. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin. Infect. Dis. 35:348-349. http://dx.doi.org/10.1086/341310.
37. Thoemmes F. 2012. Propensity score matching in SPSS. arXiv 1201: 6385v1. http://arxiv.org/ftp/arxiv/papers/1201/1201.6385.pdf.